IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Hu, Shimin1; Xu-Monette, Zijun Y.1; Tzankov, Alexander2; Green, Tina3; Wu, Lin4; Balasubramanyam, Aarthi4; Liu, Wei-min4; Visco, Carlo5; Li, Yong6; Miranda, Roberto N.1; Montes-Moreno, Santiago7; Dybkaer, Karen8; Chiu, April9; Orazi, Attilio10; Zu, Youli11; Bhagat, Govind12,13; Richards, Kristy L.14; Hsi, Eric D.15; Choi, William W. L.16; Zhao, Xiaoying17; van Krieken, J. Han18; Huang, Qin19; Huh, Jooryung20; Ai, Weiyun21; Ponzoni, Maurilio22; Ferreri, Andres J. M.22; Zhou, Fan23; Slack, Graham W.24,25; Gascoyne, Randy D.24,25; Tu, Meifeng26; Variakojis, Daina27; Chen, Weina28; Go, Ronald S.29; Piris, Miguel A.7; Moller, Michael B.3; Medeiros, L. Jeffrey1; Young, Ken H.1
刊名BLOOD
2013-05-16
DOI10.1182/blood-2012-10-460063
121期:20页:4021-4031
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]NF-KAPPA-B ; MOLECULAR SUBTYPES ; PREDICTS SURVIVAL ; R-CHOP ; PLUS CYCLOPHOSPHAMIDE ; PROGNOSTIC IMPACT ; BCL-2 EXPRESSION ; POOR-PROGNOSIS ; DISTINCT ; T(14/18)
英文摘要

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein coexpression occurred significantly more commonly in the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2 coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression. DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP.

语种英语
WOS记录号WOS:000321871900006
项目编号19001 ; 269 ; R01CA138688 ; 1RC1CA146299 ; P50CA136411 ; P50CA142509
资助机构Hematopathology Research Fellowship Award ; Shannon Timmins Leukemia Fellowship Award at The University of Texas MD Anderson Cancer Center ; Cancer Terry Fox program ; Stiftung zur Krebsbekaempfung Zurich ; The University of Texas MD Anderson Cancer Center Institutional R &amp ; D Fund, Institutional Research Grant Award ; MD Anderson Lymphoma Specialized Programs of Research Excellence Development Program Award ; MD Anderson Myeloma Specialized Programs of Research Excellence Research Development Program Award ; Gundersen Lutheran Medical Foundation Award ; MD Anderson Collaborative Funds with Roche Molecular System ; HTG Molecular Diagnostic ; Daiichi Sankyo Pharm ; National Cancer Institute/National Institutes of Health
引用统计
被引频次:268[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56306
专题北京大学临床肿瘤学院
作者单位1.Hosp Univ Marques de Valdecilla, Santander, Spain
2.Ist Sci San Raffaele, Milan, Italy
3.Aarhus Univ Hosp, Aalborg Hosp, Aalborg, Denmark
4.Southwest Washington Med Ctr, Vancouver, WA USA
5.Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
6.BC Canc Agcy, Vancouver, BC, Canada
7.BC Canc Res Ctr, Vancouver, BC, Canada
8.Cornell Univ, Weill Med Coll, New York, NY 10021 USA
9.Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
10.Methodist Hosp, Houston, TX 77030 USA
11.Columbia Univ, Med Ctr, New York, NY USA
12.New York Presbyterian Hosp, New York, NY USA
13.San Bortolo Hosp, Vicenza, Italy
14.Univ Louisville, Louisville, KY 40292 USA
15.Ameripath Quest Diagnost, Dallas, TX USA
16.Gundersen Lutheran Hlth Syst, La Crosse, WI USA
17.Cleveland Clin, Cleveland, OH 44106 USA
18.City Hope Natl Med Ctr, Duarte, CA 91010 USA
19.Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
20.Univ Basel Hosp, CH-4031 Basel, Switzerland
21.Odense Univ Hosp, DK-5000 Odense, Denmark
22.Roche Mol Syst, Pleasanton, CA USA
23.Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
24.Univ N Carolina, Sch Med, Chapel Hill, NC USA
25.Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China
26.Zhejiang Univ, Sch Med, Univ Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China
27.Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
28.Univ Calif San Francisco, Sch Med, San Francisco, CA USA
29.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Hu, Shimin,Xu-Monette, Zijun Y.,Tzankov, Alexander,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program[J]. BLOOD,2013,121(20):4021-4031.
APA Hu, Shimin.,Xu-Monette, Zijun Y..,Tzankov, Alexander.,Green, Tina.,Wu, Lin.,...&Young, Ken H..(2013).MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.BLOOD,121(20),4021-4031.
MLA Hu, Shimin,et al."MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program".BLOOD 121.20(2013):4021-4031.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hu, Shimin]的文章
[Xu-Monette, Zijun Y.]的文章
[Tzankov, Alexander]的文章
百度学术
百度学术中相似的文章
[Hu, Shimin]的文章
[Xu-Monette, Zijun Y.]的文章
[Tzankov, Alexander]的文章
必应学术
必应学术中相似的文章
[Hu, Shimin]的文章
[Xu-Monette, Zijun Y.]的文章
[Tzankov, Alexander]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。